Crossmark

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Crossref DOI link: https://doi.org/10.1038/s41573-018-0007-y

Published Online: 2019-01-04

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Galon, Jérôme https://orcid.org/0000-0001-9635-1339
Bruni, Daniela
License Information

Text and Data Mining valid from 2019-01-04
More Information

Article History

First Online: 4 January 2019

Competing interests

: Immunoscore is a registered trademark from INSERM. J.G. is co-founder and chairman of the scientific advisory board of HalioDx. J.G. has patents associated with an ‘in vitro method for the prognosis of progression of a cancer’ (PCT/IB2006/003168 and PCT/EP2013/062405). J.G. established Collaborative Research Agreement (grants) with Perkin-Elmer, IO Biotech, MedImmune, Astra Zeneca, Janssen, Imcheck Therapeutics. J.G. participated to Scientific Advisory Boards of BMS, MedImmune, Astra Zeneca, Novartis, Definiens, Merck Serono, IO Biotech, ImmunID, Nanostring, Illumina, Northwest Biotherapeutics, Actelion, Amgen, Kite Pharma and Merck MSD. J.G. was a consultant for BMS, Roche, GSK, Compugen, Mologen and Sanofi.